44 completed. 44 Phase 2, 7 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 44 | Completed 44 |
| Phase 1 | 7 | Completed 7 |
| Phase 3 | 2 | Completed 2 |
Follow Dengue: new trials by email Literature Review of Dengue trials Research Report on Dengue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan TDV, Placebo - Dengue Fever | Phase 2 / Phase 3 | Completed | Takeda | 187 | 2025-01-31 | 2025-12-30 |
| A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection AV-1 100 mg, AV-1 300 mg, AV-1 900 mg - DENV-3 Controlled Human Infection Model | Phase 2 | Completed | AbViro LLC | 85 | 2025-01-07 | 2026-03-31 |
| Study to Examine the Effects of Oral Fenretinide ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo - Dengue | Phase 2 | Completed | Island Pharmaceuticals | 15 | 2024-09-05 | 2025-10-24 |
| Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients CPLE, Placebo - Dengue Fever | Phase 1 / Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 184 | 2024-06-01 | 2025-04-25 |
| Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002) V181, Butantan - DV - Dengue | Phase 2 | Completed | Butantan Institute | 1364 | 2023-02-15 | 2025-11-18 |
| An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose - Dengue | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2022-02-03 | 2026-11-04 |
| Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients Montelukast, Placebo - Dengue, Dengue With Warning Signs | Phase 2 / Phase 3 | Completed | Phramongkutklao College of Medicine and Hospital | 358 | 2021-01-15 | 2023-07-18 |
| Metformin in Dengue With Obesity Metformin - Dengue, Viral Infection | Phase 1 / Phase 2 | Completed | Oxford University Clinical Research Unit, Vietnam | 120 | 2020-07-27 | 2023-08-31 |
| Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults CYD Dengue Vaccine, Placebo (NaCl 0.9%) vaccine group - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 133 | 2019-11-06 | 2024-07-19 |
| Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults TDV - Dengue Fever | Phase 2 | Completed | Takeda | 30 | 2018-12-28 | 2025-09-08 |
| Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan Tetravalent live attenuated dengue vaccine admixture TV005, Placebo - Dengue | Phase 2 | Completed | National Taiwan University Hospital | 252 | 2018-10-15 | 2023-01-18 |
| Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Ivermectin - Dengue Hemorrhagic Fever | Phase 2 | Completed | Mahidol University | 24 | 2018-09-04 | 2021-02-24 |
| A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan TV003, Placebo for TV003 - Dengue | Phase 2 | Completed | Medigen Vaccine Biologics Corp. | 54 | 2017-12-12 | 2019-08-14 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule CYD Dengue Vaccine (5 dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 118 | 2016-07-01 | 2022-03-24 |
| Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age CYD Dengue Vaccine, Placebo (Sodium chloride 0.9%) - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1050 | 2016-05-02 | 2022-03-24 |
| Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule CYD Dengue Vaccine (5-dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 251 | 2016-04-14 | 2022-03-24 |
| Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh TV005 vaccine, Placebo - Dengue | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 192 | 2016-03-01 | 2025-01-17 |
| Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution. - Dengue | Phase 1 / Phase 2 | Completed | U.S. Army Medical Research and Development Command | 140 | 2015-08-01 | 2019-09-25 |
| Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore Takeda's Tetravalent Dengue Vaccine Candidate (TDV), Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) - Dengue Fever | Phase 2 | Completed | Takeda | 351 | 2015-06-03 | 2019-08-28 |
| Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants Takeda's Tetravalent Dengue Vaccine Candidate (TDV), TDV Placebo - Dengue Fever | Phase 2 | Completed | Takeda | 1800 | 2014-12-05 | 2020-02-24 |
Showing 20 of 44. Sign in to see all of them.
Severe Dengue (20) · Virus Diseases (2) · Acquired Immunodeficiency Syndrome (1) · Obesity (1) · Overweight (1) · Yellow Fever (1)
Arbovirus Infections (44) · Flaviviridae Infections (44) · Flavivirus Infections (44) · Hemorrhagic Fevers, Viral (44) · Infections (44) · Mosquito-Borne Diseases (44) · RNA Virus Infections (44) · Vector Borne Diseases (44) · Virus Diseases (42) · Blood-Borne Infections (1) · Body Weight (1) · Communicable Diseases (1) · Genital Diseases (1) · HIV Infections (1)
Sodium Chloride (6) · ChimeriVax (2) · Dengue Vaccines (2) · Dosage Forms (2) · Vaccines (2) · adacel (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Chickenpox Vaccine (1) · Fenretinide (1) · Hepatitis A Vaccines (1) · Ivermectin (1) · Japanese Encephalitis Vaccines (1) · Measles-Mumps-Rubella Vaccine (1) · Metformin (1) · Pneumococcal Vaccines (1)
Sanofi Pasteur, a Sanofi Company (14) · U.S. Army Medical Research and Development Command (7) · Takeda (5) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Sanofi (3) · AbViro LLC (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Butantan Institute (1) · GlaxoSmithKline (1) · Island Pharmaceuticals (1) · Mahidol University (1) · Medigen Vaccine Biologics Corp. (1) · National Taiwan University Hospital (1) · Novo Nordisk A/S (1) · Oxford University Clinical Research Unit, Vietnam (1)
United States (11) · Thailand (9) · Brazil (4) · Philippines (4) · Singapore (4) · Colombia (3) · Mexico (3) · Puerto Rico (3) · Bangladesh (2) · Honduras (2) · Taiwan (2) · Vietnam (2) · Australia (1) · Dominican Republic (1) · India (1)
Veerachai Watanaveeradej, MD (2) · Alberto Santiago-Cornier, MD (1) · Anna Durbin, MD (1) · Anna Quintero, MD (1) · Bert Slade, MD (1) · Beth D. Kirkpatrick, MD (1) · Clemente Diaz-Perez, MD (1) · Domingo Chardon-Feliciano, MD (1) · Evelyn Matta-Fontanet, MD (1)
PMID 40099800, PMID 32932330, PMID 16269927, PMID 18337339, PMID 21813857, PMID 21976579, PMID 22863660, PMID 22894958, PMID 22975340, PMID 23208878, PMID 23540847, PMID 23839107, PMID 24021313, PMID 24067553, PMID 24189367, PMID 24865677, PMID 24877997, PMID 25483647, PMID 26175027, PMID 26214039, PMID 26291554, PMID 27102820, PMID 27509020, PMID 28365225, PMID 29122463, PMID 29897841, PMID 30241510, PMID 30986790, PMID 31464558, PMID 31843269, PMID 32119591, PMID 32197107, PMID 32342848, PMID 32572472, PMID 33083561, PMID 33212067, PMID 33534885, PMID 33626291, PMID 33711074, PMID 33822015, PMID 35078666, PMID 35364022, PMID 37776876, PMID 38306389, PMID 39308445, PMID 39356094, PMID 40591696, PMID 41213642, PMID 41297006, PMID 41722532
2014 (4), 2018 (1)